Promomed launches the innovative import-substituting drug product Enligria for the treatment of overweight and obesity

Promomed Group, one of the leaders of the Russian pharmaceutical market, announced the launch of the first drug in Russia belonging to the glutide group (glucagon-like peptide receptor agonists) for the treatment of overweight and obese patients, as well as for the prevention of cardiovascular complications associated with these diseases.

The new line of drugs includes Enligria, Quinliro (INN liraglutide) and Quincenta (INN semaglutide). Earlier, the drug under trade name Enligria (prefilled syringes) received marketing authorization certificate. Enligria will be available in pharmacies in the second decade of October this year. Quinliro and Quincenta are at the stage of approval.

Liraglutide is one of the most potent stimulants of insulin production, which allows a patient to achieve stable control of blood sugar levels. The drug also slows down digestion, which helps to avoid sudden blood sugar spikes after meals. Thanks to this, diabetic patients can achieve stable blood sugar control and improve their quality of life. An important aspect is that liraglutide can be used either as monotherapy or in combination with other drugs, depending on the patient's specific situation. This gives doctors more opportunities to use personal approach to treatment and achieve optimal results.

The drug substance of Enligria is liraglutide produced by chemical synthesis, which is 97% homologous in amino acid composition to human GLP-1, is resistant to metabolisation, and therefore is has a long half-life in plasma (T½ = 13 hours), which makes it suitable for one daily dosage. The drug offers a more significant effect on the hunger and satiety center, which provides weight loss through increasing the feeling of satiety, reducing the feeling of hunger and food intake.

The studies demonstrated that liraglutide 3 mg has an optimal efficacy and safety profile for the treatment of obesity proven in randomized clinical trials and in real clinical practice studies. The launch of domestic GLR agonists Enligria, Quinliro (liraglutide), and Quincenta (semaglutide) will cover the shortage of similar drugs that emerged in Russia in 2022 when a sole manufacturer stopped deliveries.

Ivan Dedov, Academician of the Russian Academy of Sciences, President of the National Medical Research Center for Endocrinology of the Russian Ministry of Health:
“The problem of overweight affects half of the population of our country, and more than 30 million people are obese. Obesity is a key risk factor for the development of disabling diseases and life-threatening conditions (heart attacks, strokes and other cardiovascular complications). Overweight also reduces reproductive health and poses a threat to the reproductive potential of the country. Risks caused by metabolic health disorders cannot be reduced without a reduction in excess weight. From now, the doctors have access to a wide range of domestic drugs for personalized treatment of each patient.”

Petr Bely, Chairman of the Board of Directors of Promomed Group:
“The decision to start developing a group of drugs based on glutides has become a completely logical and natural step for our team, because we have been working in the field of endocrinology for many years, and the development of this drug was carried out in close cooperation with the leading endocrinologists of our country. At the heart of our strategy is maximum support for the national pharmaceutical security. Our mission is to provide each Russian patient with innovative, highly effective and affordable drugs as soon as possible. The result achieved today is based on many years of systematic work in the field of developing new technologies for the full cycle of production of demanded and vital medicines for the Russian market.”